Mirati Therapeutics announced that new data from the ongoing Phase 1b clinical trial of single agent sitravatinib will be presented at the 2018 American Society of Clinical Oncology, or ASCO, annual meeting. The data will highlight initial results from the cohort evaluating sitravatinib in the treatment of patients with metastatic renal cell carcinoma, or mRCC, who are refractory to anti-angiogenic therapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.